✦ LIBER ✦
5072 Independent central review of clinical benefit rates in FIRST: a Phase II comparison of fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor positive advanced breast cancer
✍ Scribed by J.P.O. Lindemann; J.F.R. Robertson; M.J. Ellis; Y. Menu; E.J. Macpherson; D.D.C. Ghiorghiu
- Book ID
- 119600722
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 49 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.